[go: up one dir, main page]

MX2016005858A - Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales. - Google Patents

Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales.

Info

Publication number
MX2016005858A
MX2016005858A MX2016005858A MX2016005858A MX2016005858A MX 2016005858 A MX2016005858 A MX 2016005858A MX 2016005858 A MX2016005858 A MX 2016005858A MX 2016005858 A MX2016005858 A MX 2016005858A MX 2016005858 A MX2016005858 A MX 2016005858A
Authority
MX
Mexico
Prior art keywords
cysteamine
derivatives
inherited
acquired
mitochondrial
Prior art date
Application number
MX2016005858A
Other languages
English (en)
Inventor
Rioux Patrice
C Zankel Todd
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of MX2016005858A publication Critical patent/MX2016005858A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente revelación se refiere a métodos para tratar la enfermedad mitocondrial heredada o adquirida mediante el uso de un producto de cisteamina, por ejemplo, cisteamina o cistamina o derivados de estas.
MX2016005858A 2013-11-06 2014-11-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales. MX2016005858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900772P 2013-11-06 2013-11-06
PCT/US2014/064336 WO2015069888A2 (en) 2013-11-06 2014-11-06 Use of cysteamine and derivatives thereof to treat mitochondrial diseases

Publications (1)

Publication Number Publication Date
MX2016005858A true MX2016005858A (es) 2016-08-11

Family

ID=53007221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005858A MX2016005858A (es) 2013-11-06 2014-11-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales.

Country Status (13)

Country Link
US (1) US20150125526A1 (es)
EP (1) EP3065725A4 (es)
JP (1) JP2016540827A (es)
KR (1) KR20160070154A (es)
CN (1) CN105873579A (es)
CA (1) CA2928442A1 (es)
CL (1) CL2016001098A1 (es)
EA (1) EA201690936A1 (es)
IL (1) IL245231A0 (es)
MX (1) MX2016005858A (es)
PH (1) PH12016500842A1 (es)
TW (1) TW201605434A (es)
WO (1) WO2015069888A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028448A2 (pt) * 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
EP3536802B1 (en) * 2016-11-02 2021-10-13 Kyoto University Effectiveness determination marker in disease treatment by pd-1 signal inhibitor
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
JP2024510442A (ja) * 2021-03-19 2024-03-07 アークサーダ・リミテッド・ライアビリティ・カンパニー 殺生物組成物及び方法
JP7427308B2 (ja) * 2021-05-24 2024-02-05 国立大学法人岩手大学 網膜の神経細胞の保護剤
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299545A2 (en) * 2000-07-07 2003-04-09 Incyte Genomics, Inc. Drug metabolizing enzymes
WO2011069002A1 (en) * 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease

Also Published As

Publication number Publication date
WO2015069888A2 (en) 2015-05-14
WO2015069888A3 (en) 2015-11-12
EP3065725A4 (en) 2017-06-14
IL245231A0 (en) 2016-06-30
JP2016540827A (ja) 2016-12-28
US20150125526A1 (en) 2015-05-07
CN105873579A (zh) 2016-08-17
EP3065725A2 (en) 2016-09-14
EA201690936A1 (ru) 2016-08-31
KR20160070154A (ko) 2016-06-17
PH12016500842A1 (en) 2016-07-04
CL2016001098A1 (es) 2016-12-23
TW201605434A (zh) 2016-02-16
CA2928442A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
PH12016500842A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON&#39;S DISEASE
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
MX394266B (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
SMT202000305T1 (it) Composizioni per l&#39;uso in metodi per il trattamento di ferite, disturbi e malattie della pelle
EA201591535A1 (ru) Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств
SG11201509729YA (en) Use of high dose pridopidine for treating huntington&#39;s disease
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
PT3307293T (pt) Formulações para o tratamento de distúrbios da boca, garganta e trato respiratório
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases
BR112017009193A2 (pt) método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica